Skip to main content
. 2017 May 24;8(34):56893–56905. doi: 10.18632/oncotarget.18137

Figure 2. Effects of combined treatment of erlotinib or gefitinib with MTE on cell viability and apoptosis in HCC827/ER cells.

Figure 2

(A) The viability of parental HCC827 cells and resistant HCC827/ER cells after treatment with the indicated concentration of MTE for 72h. HCC827/ER cells were treated with erlotinib (B), gefitinib (C), or three different combinations of 8 mg/ml MTE and one of the other 2 drugs for 72 hours. Results were expressed as the percentage of living cells compared to the control, and error bars indicated SD of three independent measurements.*p < 0.05, *p < 0.01 vs control group. Combined effects were measured using the MTT assay and CI values (D). Cell apoptosis was determined by flow cytometry (E) after treatment with 1 μM erlotinib and gefitinib alone or their respective combinations with 8 mg/ml MTE (M→M+E for erlotinib, M→M+G for gefitinib) in HCC827/ER cells. (F) Quantitative results for Figure E. Each bar represents mean ± SD of three separate experiments. *p < 0.05, *p < 0.01 vs control group, #p < 0.05 vs combinations of erlotinib or gefitinib with MTE. Con: control; G: gefitinib; E: erlotinib; MTE: Marsdenia tenacissima extract.